drugset / Trial / NCT06959706
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
Timeline
- Start
- 2025-05-07
- Primary completion
- 2026-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGW101-ADC | Other / unclassified | — | Intravenous |
| Background | TRG001 | Small molecule | — | — |